Australija - engleski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - minoxidil, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; maize starch; colloidal anhydrous silica - indications as at 1 january 1991 : indicated as adjunctive therapy in adults with severe refractory hypertension which has failed to respond to extensive multiple therapy. when used in combination with an accompanying diuretic and beta-blocker, minoxidil (loniten) has been shown to reverse encephalopathy and retinopathy in severe hypertensives.

Izrael - engleski - Ministry of Health

bayer israel ltd - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), adults (following completion of at least 6 months therapy for dvt or pe).

Izrael - engleski - Ministry of Health

bayer israel ltd - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), adults (following completion of at least 6 months therapy for dvt or pe).

Izrael - engleski - Ministry of Health

bayer israel ltd - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), adults (following completion of at least 6 months therapy for dvt or pe).

Izrael - engleski - Ministry of Health

bayer israel ltd - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), adults (following completion of at least 6 months therapy for dvt or pe).

Japan - engleski - すりの適正使用協議会 RAD-AR Council, Japan

bayer yakuhin, ltd. - aflibercept (genetical recombination) - injection

Japan - engleski - すりの適正使用協議会 RAD-AR Council, Japan

santen pharmaceutical co.,ltd. - aflibercept (genetical recombination) - injection

Japan - engleski - すりの適正使用協議会 RAD-AR Council, Japan

novartis pharma k.k. - ranibizumab(genetical recombination) - injection

Europska Unija - engleski - EMA (European Medicines Agency)

allergan pharmaceuticals ireland - bimatoprost, timolol - glaucoma, open-angle, ocular hypertension - ophthalmologicals, - reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Europska Unija - engleski - EMA (European Medicines Agency)

accord healthcare s.l.u. - docetaxel - head and neck neoplasms, carcinoma, non-small-cell lung, adenocarcinoma, prostatic neoplasms, breast neoplasms - antineoplastic agents, - breast cancerdocetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w